Navigation Links
Pathway for Biosimilars Act Protects Patients, Promotes Competition, Preserves Innovation and Creates Quality Jobs, Lilly Says
Date:3/17/2009

l new biological drugs a base period of 12 years of data protection with the right to obtain an additional two years once a further indication for use of the product is approved by the FDA.

Today, strong patents, when they exist, can protect all types of medicines from competition, including protection from generic copies. However, effective patent protection is sometimes unavailable or available only for a very limited period once a new medicine gets to market. In both these situations, patent protection by itself can be insufficient to secure a fair return on the research investments needed to get the new medicine to market - thus risking the system by which new cures and treatments are found. These and other patent shortcomings are magnified for biological drugs because of their relative complexity and the greater uncertainty in how patent laws will eventually apply to them.

In addition to strong patents, "data protection" would offer additional needed protections for innovative biological medicines. Data protection, unlike patents, sets out a consistent, defined period in which copied versions of a new biological drug can only come to market if it follows the same rigorous testing requirements that the innovator undertook to gain FDA approval.

Thus, through an adequate period of data protection, patients and their physicians can be assured of a more complete safety and effectiveness track record before "follow-on" or biosimilar products come to market - important because of consistency and purity concerns. Significantly, Eshoo-Inslee-Barton's approach to data protection is consistent with the earlier Senate-approved approach.

Armitage noted that the biotech industry that creates life-saving biologic medicines boosts the U.S. economy and provides high-paying American jobs. According to the Bureau of Labor Statistics, the biosciences sector is expected to add 69,000 U.S. manufacturing
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions
2. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
3. Millipore Launches an Interactive Biological Pathway Tool Using GeneGos Manually Curated Pathway Maps
4. Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
5. GEN Reports Growing Focus on PI3-Kinase Pathway in Cancer Research
6. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
7. Frost & Sullivan Awards Genpathway 2008 Healthcare Innovation Award
8. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
9. Pathway Diagnostics Announces Commercial Availability of Second Generation SensiTrop(TM) II Molecular HIV Co-receptor Tropism Assay
10. Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimers Disease
11. Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
(Date:10/20/2014)... OR (PRWEB) October 20, 2014 Local ... participate in an investigational study of donor stem cells ... in stem cell therapy and has performed clinical stem ... this study is to determine if a single injection ... affected joints can help reduce pain and inflammation in ...
(Date:10/19/2014)... 19, 2014 NextCODE Health, which enables clinicians and ... real time, today announced the launch of its new genomic ... at the American Society of Human Genetics (ASHG) annual meeting ... sign up and apply for free beta access, visit ... benefits can be viewed here . The ...
(Date:10/19/2014)... 2014 The Asia-Pacific Speech Analytics market ... Asia-Pacific with analysis and forecast of revenue. This market ... to $208 million by 2019, at a Compound Annual ... , Browse through the TOC of the Asia-Pacific Speech ... in-depth analysis provided. It also provides a glimpse of ...
Breaking Biology Technology:PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4
... Plexus Corp. (Nasdaq:,PLXS), today announced it will release its fiscal 2008 ... April 23rd after,the stock market closes. Senior management will host a ... 24th at 8:30 a.m.,Eastern Time., What: ... When: Thursday, April 24th at 8:30 a.m. ...
... from Continuing Operations Driven by ... Continuing Operations of $1.3 Billion ... First Quarter 2008 GAAP EPS from Continuing Operations of $0.35 Compared ... Continuing Operations of $0.42 Compared to $0.36 ...
... Commercial Operating ... ... ; MTAX) today announced that Craig W. Philips, most recently,Vice President ... CTI with direct responsibilities for all Development and,Commercial Operations, effective August ...
Cached Biology Technology:Plexus Q2 Earnings Release on April 23rd After Market Close and Conference Call on April 24th at 8:30 am E.T. 2Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 2Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 3Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 4Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 5Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 6Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 7Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 8Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 9Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 10Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 11Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 12Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 13Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 14Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 15Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 16Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 17Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 18Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 19Veteran Drug Industry Executive to Become President of CTI 2Veteran Drug Industry Executive to Become President of CTI 3Veteran Drug Industry Executive to Become President of CTI 4
(Date:10/17/2014)... is available in German . ... sperms every day in order to reproduce? And why are ... topic of the latest issue of the research journal ... evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has compiled ... not unusual for a female to copulate with several males ...
(Date:10/16/2014)... wages war on the human body. Battles are ... In pancreatic cancer, this stalemate—known as tumor dormancy—can ... malignant, a phenomena that is poorly understood. ... laboratory of Salvatore Torquato, a Professor of Chemistry ... surrounding tumor dormancy and the switch to a ...
(Date:10/16/2014)... have challenged conventional thinking on how the bowel lining ... for how bowel cancer starts. , The researchers produced ... regenerating the ,crypts, that are a feature of the ... in bowel cancer development, a controversial finding as scientists ... Using 3D imaging technologies, Dr Chin Wee Tan and ...
Breaking Biology News(10 mins):Sperm wars 2Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2
... Researchers in Australia are developing diversionary tactics to ... those responsible for major gut infections, such as cholera, ... to complex sugar receptors displayed on the surface of ... Society for General Microbiology,s meeting at Heriot-Watt University, Edinburgh, ...
... fat removed during liposuction conceal versatile cells that are ... stem cells, or iPS cells, than are the skin ... new study from Stanford,s School of Medicine. "We,ve identified ... co-author of the research, Michael Longaker, MD, who has ...
... Bacteria that generate significant amounts of electricity could be ... remote environments or to convert waste to electricity. Professor ... bacteria with large numbers of tiny projections called pili ... power in fuel cells than bacteria with a smooth ...
Cached Biology News:Designing probiotics that ambush gut pathogens 2'Liposuction leftovers' easily converted to IPS cells, Stanford study shows 2'Liposuction leftovers' easily converted to IPS cells, Stanford study shows 3
... 2-color staining method for labeling DNA breaks ... cells by flow cytometry. The kit contains ... apoptosis in cells including positive and negative ... reaction and rinsing buffers for processing individual ...
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
... the latest entry in the Biomek line. With ... increased robustness, it can meet the needs of ... with either one or two pipetting pods. With ... the standard for flexible laboratory solutions to meet ...
... By incorporating a wide range of ... NX sets a new standard for flexible ... liquid handling including pipetting, dilution, dispensing, ... system thats as powerful and flexible as ...
Biology Products: